#1 Clinical Trials Search in Europe

Pimavanserin Tartrate

Pimavanserin Tartrate, also known as ACP-103, is a drug being studied in clinical trials for its potential to treat psychosis associated with Parkinson’s disease and other conditions. These trials aim to evaluate the safety, efficacy, and long-term effects of Pimavanserin in reducing hallucinations and delusions while monitoring its impact on motor symptoms. The research spans various dosages and durations, providing valuable insights into this promising treatment option.

Table of Contents

What is Pimavanserin?

Pimavanserin tartrate, also known by its brand name Nuplazid, is a medication primarily used to treat certain mental health symptoms associated with neurological disorders[1]. It belongs to a class of drugs called atypical antipsychotics, which work differently from traditional antipsychotic medications[2].

What Conditions Does Pimavanserin Treat?

Pimavanserin is primarily used to treat the following conditions:

  • Parkinson’s Disease Psychosis (PDP): This is a condition where people with Parkinson’s disease experience hallucinations (seeing or hearing things that aren’t there) or delusions (false beliefs)[1][3].
  • Alzheimer’s Disease Psychosis: Similar to PDP, this condition involves psychotic symptoms in people with Alzheimer’s disease[4].
  • Agitation and Aggression in Alzheimer’s Disease: Pimavanserin is being studied for its potential to manage these behavioral symptoms in Alzheimer’s patients[5].

Ongoing research is also exploring its potential use in other conditions, such as Autism Spectrum Disorder, particularly for treating rigid-compulsive behaviors[6].

How Does Pimavanserin Work?

Pimavanserin works differently from other antipsychotic medications. It targets specific receptors in the brain called serotonin receptors, particularly the 5-HT2A receptor. By blocking these receptors, pimavanserin can help reduce hallucinations and delusions without significantly affecting motor function, which is particularly important for Parkinson’s disease patients[2].

Dosage and Administration

The dosage of pimavanserin can vary depending on the condition being treated and individual patient factors. However, based on the clinical trials, common dosages include:

  • 34 mg once daily (often given as two 17 mg tablets)[7]
  • 20 mg once daily[5]
  • 40 mg once daily (given as two 20 mg tablets)[4]

Pimavanserin is typically taken orally (by mouth) once daily. It’s important to take the medication exactly as prescribed by your healthcare provider[2].

Clinical Trials and Efficacy

Multiple clinical trials have been conducted to evaluate the safety and efficacy of pimavanserin:

  • For Parkinson’s Disease Psychosis: Studies have shown that pimavanserin can significantly reduce hallucinations and delusions in PDP patients. This is typically measured using scales like the Scale for the Assessment of Positive Symptoms (SAPS) or its modified version for Parkinson’s disease (SAPS-PD)[2].
  • For Alzheimer’s Disease Psychosis: Research has indicated potential benefits in reducing psychotic symptoms in Alzheimer’s patients, as measured by the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH)[4].
  • For Agitation and Aggression in Alzheimer’s Disease: Ongoing studies are assessing its effectiveness using measures like the Cohen-Mansfield Agitation Inventory (CMAI)[5].

Importantly, studies have also shown that pimavanserin does not significantly worsen motor symptoms in Parkinson’s disease patients, which is a common concern with other antipsychotic medications[1].

Potential Side Effects

As with all medications, pimavanserin can cause side effects. Common side effects may include:

  • Nausea
  • Constipation
  • Confusion
  • Headache
  • Changes in balance or walking

It’s important to report any side effects to your healthcare provider. They can help determine if the benefits of the medication outweigh the risks for your individual situation[8].

Ongoing Research

Research on pimavanserin is ongoing, with several studies exploring its potential use in other conditions:

  • Autism Spectrum Disorder: A study is investigating whether pimavanserin can help with behavioral inflexibility and rigid-compulsive behaviors in individuals with autism[6].
  • Long-term Safety: Studies are continuing to assess the long-term safety and tolerability of pimavanserin in various patient populations[9].

As research progresses, our understanding of pimavanserin’s potential uses and effects may expand, potentially offering new treatment options for various neurological and psychiatric conditions.

Aspect Details
Primary Conditions Studied Parkinson’s Disease Psychosis, Alzheimer’s Disease Psychosis, Autism Spectrum Disorder
Main Dosages 10 mg, 20 mg, 34 mg, 40 mg
Administration Oral tablets or capsules, once daily
Typical Study Duration 6 weeks (with some longer-term extensions)
Primary Outcome Measures Changes in psychosis symptoms (hallucinations and delusions)
Secondary Outcome Measures Motor symptoms, safety, and tolerability
Assessment Tools SAPS, UPDRS, NPI-NH, RBS-R
Study Designs Placebo-controlled, double-blind, randomized, open-label extensions

FAQ

  • What is Pimavanserin Tartrate used for in clinical trials? Pimavanserin Tartrate is primarily being studied for the treatment of psychosis in Parkinson's disease. It's also being investigated for potential use in Alzheimer's disease psychosis and autism spectrum disorder.
  • How is the effectiveness of Pimavanserin measured in these trials? The effectiveness is mainly measured using scales that assess the severity and frequency of hallucinations and delusions, such as the Scale for the Assessment of Positive Symptoms (SAPS) or the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) for Alzheimer's patients.
  • What are the common dosages of Pimavanserin used in the trials? The trials have explored various dosages, including 10 mg, 20 mg, 34 mg, and 40 mg, typically administered as tablets or capsules once daily by mouth.
  • Are there any concerns about Pimavanserin's effect on motor symptoms in Parkinson's disease? The trials monitor motor symptoms using the Unified Parkinson's Disease Rating Scale (UPDRS). So far, the studies aim to ensure that Pimavanserin does not worsen motor symptoms while treating psychosis.
  • How long do the clinical trials for Pimavanserin typically last? The duration varies, but many of the trials last for 6 weeks. Some studies also include longer-term open-label extensions to assess long-term safety and tolerability.

Ongoing Clinical Trials on Pimavanserin Tartrate

  • Study on the Long-Term Safety of Pimavanserin for Treating Irritability in Children and Adolescents with Autism Spectrum Disorder

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Hungary Italy Poland Spain

Glossary

  • Parkinson's Disease Psychosis (PDP): A condition where people with Parkinson's disease experience hallucinations (seeing or hearing things that aren't there) or delusions (false beliefs).
  • Placebo: A substance that looks like the real medicine but contains no active drug. It's used in clinical trials to compare the effects of the actual drug.
  • Double-Blind: A study design where neither the participants nor the researchers know who is receiving the real drug or the placebo.
  • Efficacy: How well a treatment works in ideal conditions, usually measured in clinical trials.
  • Scale for the Assessment of Positive Symptoms (SAPS): A tool used to measure the severity of psychotic symptoms, particularly hallucinations and delusions.
  • Unified Parkinson's Disease Rating Scale (UPDRS): A comprehensive system used to assess motor and non-motor symptoms in Parkinson's disease patients.
  • Open-Label Extension: A phase of a clinical trial where all participants receive the active drug, often used to gather long-term safety data.
  • Antipsychotic: A type of medication used to manage psychosis, including hallucinations and delusions.
  • Neuropsychiatric Inventory-Nursing Home Version (NPI-NH): A questionnaire used to evaluate behavioral changes in dementia patients, including those with Alzheimer's disease.

References

  1. https://clinicaltrials.gov/study/NCT00658567
  2. https://clinicaltrials.gov/study/NCT01174004
  3. https://clinicaltrials.gov/study/NCT02762591
  4. https://clinicaltrials.gov/study/NCT02035553
  5. https://clinicaltrials.gov/study/NCT02992132
  6. https://clinicaltrials.gov/study/NCT05999240
  7. https://clinicaltrials.gov/study/NCT06068465
  8. https://clinicaltrials.gov/study/NCT00550238
  9. https://clinicaltrials.gov/study/NCT01518309